Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Group 1: Nasdaq Biotechnology Index Inclusion - Alvotech's stock will be added to the Nasdaq Biotechnology Index (NBI) as part of the annual reconstitution, effective December 23, 2024 [5] - The Nasdaq Biotechnology Index includes companies classified as Biotechnology or Pharmaceuticals, calculated under a modified capitalization-weighted methodology [1] Group 2: Company Overview - Alvotech is focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space with high-quality, cost-effective products [2] - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [2] - Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting various diseases, including autoimmune disorders and cancer [2] Group 3: Strategic Partnerships - Alvotech has established a network of strategic commercial partnerships to enhance its global reach, including collaborations with Teva Pharmaceuticals, STADA Arzneimittel AG, and others across various regions [2] - Each partnership covers unique products and territories, leveraging local expertise in markets such as the U.S., Europe, Japan, and parts of Asia and South America [2]